Yayın:
Acute central nervous system complications in pediatric acute lymphoblastic leukemia

dc.contributor.buuauthorBaytan, Birol
dc.contributor.buuauthorEvim, Melike Sezgin
dc.contributor.buuauthorGüler, Salih
dc.contributor.buuauthorGüneş, Adalet Meral
dc.contributor.buuauthorOkan, Mehmet
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Nöroloji Ana Bilim Dalı
dc.contributor.departmentPediatrik Hematoloji Ana Bilim Dalı
dc.contributor.researcheridAAH-1452-2021
dc.contributor.scopusid6506622162
dc.contributor.scopusid36337796600
dc.contributor.scopusid55648289500
dc.contributor.scopusid24072843300
dc.contributor.scopusid6701707256
dc.date.accessioned2022-05-27T13:29:53Z
dc.date.available2022-05-27T13:29:53Z
dc.date.issued2015-10
dc.description.abstractBACKGROUND: The outcome of childhood acute lymphoblastic leukemia has improved because of intensive chemotherapy and supportive care. The frequency of adverse events has also increased, but the data related to acute central nervous system complications during acute lymphoblastic leukemia treatment are sparse. The purpose of this study is to evaluate these complications and to determine their long term outcome. PATIENTS AND METHODS: We retrospectively analyzed the hospital reports of 323 children with de novo acute lymphoblastic leukemia from a 13-year period for acute neurological complications. The central nervous system complications of leukemic involvement, peripheral neuropathy, and post-treatment late-onset encephalopathy, and neurocognitive defects were excluded. RESULTS: Twenty-three of 323 children (7.1%) suffered from central nervous system complications during acute lymphoblastic leukemia treatment. The majority of these complications (n = 13/23; 56.5%) developed during the induction period. The complications included posterior reversible encephalopathy (n = 6), fungal abscess (n = 5), cerebrovascular lesions (n = 5), syndrome of inappropriate secretion of antidiuretic hormone (n = 4), and methotrexate encephalopathy (n = 3). Three of these 23 children (13%) died of central nervous system complications, one from an intracranial fungal abscess and the others from intracranial thrombosis. Seven of the survivors (n = 7/20; 35%) became epileptic and three of them had also developed mental and motor retardation. CONCLUSIONS: Acute central neurological complications are varied and require an urgent approach for proper diagnosis and treatment. Collaboration among the hematologist, radiologist, neurologist, microbiologist, and neurosurgeon is essential to prevent fatal outcome and serious morbidity.
dc.identifier.citationBaytan, B. vd. (2015). "Acute central nervous system complications in pediatric acute lymphoblastic leukemia". Pediatric Neurology, 53(4), 312-318.
dc.identifier.doi10.1016/j.pediatrneurol.2015.03.006
dc.identifier.endpage318
dc.identifier.issue4
dc.identifier.pubmed26202590
dc.identifier.scopus2-s2.0-84941811071
dc.identifier.startpage312
dc.identifier.urihttps://doi.org/10.1016/j.pediatrneurol.2015.03.006
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0887899415001459
dc.identifier.urihttp://hdl.handle.net/11452/26743
dc.identifier.volume53
dc.identifier.wos000362056500006
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier Science
dc.relation.journalPediatric Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAbscess
dc.subjectAcute central nervous system complications
dc.subjectAcute lymphoblastic leukemia
dc.subjectALL-BFM protocols
dc.subjectCerebrovascular complications
dc.subjectChildren
dc.subjectPosterior leukoencephalopathy syndrome
dc.subjectInvasive aspergillosis
dc.subjectNeurologic complications
dc.subjectAcute neurotoxicity
dc.subjectIschemic-stroke
dc.subjectL-asparaginase
dc.subjectChildren
dc.subjectMethotrexate
dc.subjectTherapy
dc.subjectNeurosciences & neurology
dc.subjectPediatrics
dc.subject.emtreeAnticonvulsive agent
dc.subject.emtreeAntifungal agent
dc.subject.emtreeAntihypertensive agent
dc.subject.emtreeAsparaginase
dc.subject.emtreeCyclophosphamide
dc.subject.emtreeCytarabine
dc.subject.emtreeDaunorubicin
dc.subject.emtreeDexamethasone
dc.subject.emtreeDoxorubicin
dc.subject.emtreeEtoposide
dc.subject.emtreeHeparin
dc.subject.emtreeIfosfamide
dc.subject.emtreeMercaptopurine
dc.subject.emtreeMethotrexate
dc.subject.emtreePrednisolone
dc.subject.emtreeVasopressin
dc.subject.emtreeVincristine
dc.subject.emtreeAzide
dc.subject.emtreeEE 581
dc.subject.emtreeOctreotide
dc.subject.emtreeAcute lymphoblastic leukemia
dc.subject.emtreeAdolescent
dc.subject.emtreeAdverse outcome
dc.subject.emtreeAphasia
dc.subject.emtreeArticle
dc.subject.emtreeBlindness
dc.subject.emtreeBrain abscess
dc.subject.emtreeBrain disease
dc.subject.emtreeBrain hemorrhage
dc.subject.emtreeCancer combination chemotherapy
dc.subject.emtreeCancer palliative therapy
dc.subject.emtreeCancer survivor
dc.subject.emtreeCancer therapy
dc.subject.emtreeCentral nervous system aspergillosis
dc.subject.emtreeChild
dc.subject.emtreeChildhood leukemia
dc.subject.emtreeClinical evaluation
dc.subject.emtreeControlled study
dc.subject.emtreeConvulsion
dc.subject.emtreeDrug induced headache
dc.subject.emtreeDrug megadose
dc.subject.emtreeEEG abnormality
dc.subject.emtreeEpilepsy
dc.subject.emtreeFacial nerve paralysis
dc.subject.emtreeFatality
dc.subject.emtreeFemale
dc.subject.emtreeFocal epilepsy
dc.subject.emtreeHormone release
dc.subject.emtreeHuman
dc.subject.emtreeInduction chemotherapy
dc.subject.emtreeLong term care
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMedical information
dc.subject.emtreeMental deficiency
dc.subject.emtreeMotor retardation
dc.subject.emtreeNeurological complication
dc.subject.emtreeOcclusive cerebrovascular disease
dc.subject.emtreeOutcome assessment
dc.subject.emtreePosterior reversible encephalopathy syndrome
dc.subject.emtreePriority journal
dc.subject.emtreeRetrospective study
dc.subject.emtreeSchool child
dc.subject.emtreeTransient ischemic attack
dc.subject.emtreeVisual impairment
dc.subject.emtreeAnalogs and derivatives
dc.subject.emtreeBrain
dc.subject.emtreeCentral nervous system diseases
dc.subject.emtreeComplication
dc.subject.emtreeNuclear magnetic resonance imaging
dc.subject.emtreePathology
dc.subject.emtreePathophysiology
dc.subject.emtreePrecursor cell lymphoblastic leukemia-lymphoma
dc.subject.emtreePreschool child
dc.subject.meshAzides
dc.subject.meshBrain
dc.subject.meshCentral nervous system diseases
dc.subject.meshChild
dc.subject.meshChild, preschool
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMagnetic resonance imaging
dc.subject.meshMale
dc.subject.meshOctreotide
dc.subject.meshPrecursor cell lymphoblastic leukemia-lymphoma
dc.subject.meshRetrospective studies
dc.subject.scopusMethotrexate; Cytarabine; Precursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.wosClinical neurology
dc.subject.wosPediatrics
dc.titleAcute central nervous system complications in pediatric acute lymphoblastic leukemia
dc.typeArticle
dc.wos.quartileQ3 (Clinical neurology)
dc.wos.quartileQ2 (Pediatrics)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Pediatrik Hematoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Çocuk Nöroloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama